ITGAL and Keratoconjunctivitis sicca: Given Lifitegrast, an LFA-1 antagonist, has been approved by the US Food and Drug Administration for the treatment of dry eye [1], future examination of BIRT-377 as a clinically approved pain therapeutic could be achievable in the near future.